Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q92900
UPID:
RENT1_HUMAN
Alternative names:
ATP-dependent helicase RENT1; Nonsense mRNA reducing factor 1; Up-frameshift suppressor 1 homolog
Alternative UPACC:
Q92900; O00239; O43343; Q86Z25; Q92842
Background:
Regulator of nonsense transcripts 1 (UPF1) is a pivotal RNA-dependent helicase involved in the nonsense-mediated decay (NMD) pathway, crucial for identifying and degrading mRNAs with premature stop codons. Known also as ATP-dependent helicase RENT1, UPF1 modulates the expression levels of normal mRNAs, ensuring cellular homeostasis. Its activity is regulated through cycles of phosphorylation and dephosphorylation, playing a key role in the surveillance mechanism that distinguishes aberrant mRNAs.
Therapeutic significance:
Understanding the role of Regulator of nonsense transcripts 1 could open doors to potential therapeutic strategies.